Critical Review: LogicBio Therapeutics (NASDAQ:LOGC) versus Aptose Biosciences (NASDAQ:APTO)

LogicBio Therapeutics (NASDAQ:LOGC) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Profitability

This table compares LogicBio Therapeutics and Aptose Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LogicBio Therapeutics N/A -86.99% -69.95%
Aptose Biosciences N/A -53.31% -48.99%

Institutional and Insider Ownership

52.8% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 39.9% of Aptose Biosciences shares are owned by institutional investors. 49.9% of LogicBio Therapeutics shares are owned by company insiders. Comparatively, 7.3% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for LogicBio Therapeutics and Aptose Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LogicBio Therapeutics 0 0 2 0 3.00
Aptose Biosciences 0 0 5 0 3.00

LogicBio Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 191.97%. Aptose Biosciences has a consensus price target of $12.00, suggesting a potential upside of 57.48%. Given LogicBio Therapeutics’ higher probable upside, analysts plainly believe LogicBio Therapeutics is more favorable than Aptose Biosciences.

Earnings & Valuation

This table compares LogicBio Therapeutics and Aptose Biosciences’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LogicBio Therapeutics N/A N/A -$40.13 million ($1.78) -3.85
Aptose Biosciences N/A N/A -$26.28 million ($0.52) -14.65

Aptose Biosciences is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

LogicBio Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Summary

Aptose Biosciences beats LogicBio Therapeutics on 6 of the 9 factors compared between the two stocks.

About LogicBio Therapeutics

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.